...

Curriculum Vitae Education: Name: Claire Keating

by user

on
Category: Documents
28

views

Report

Comments

Transcript

Curriculum Vitae Education: Name: Claire Keating
Curriculum Vitae
Name: Claire Keating
Address: 622 West 168th Street
PH8 -859
New York, NY 10032
Education:
Cornell University, College of Agriculture and Life Sciences, Ithaca, NY
B.S. with Honors Biological Sciences, May 1997
1997
Tufts University School of Medicine, Boston, MA
MD, May 2003
2003
Postdoctural Training
New York Presbyterian Hospital – Weill Cornell Medical Center
Intern and Resident Internal Medicine
2003-2006
International Elective - Cape Town, South Africa
Respiratory Clinic, Groote Schuur Hospital/University of Cape Town
Feb 2006
New York Presbyterian Hospital – Columbia Medical Center
Fellow Pulmonary and Critical Care Medicine
2006-2009
Board Certification:
New York State License
Diplomate, American Board of Internal Medicine
Sub-specialty Pulmonary Disease
Sub-specialty Critical Care Medicine
2005
2006
2008
2009
Professional Organizations:
American Thoracic Society
American College of Chest Physicians
2006
2007
Academic Appointments:
Assistant Professor of Clinical Medicine
Columbia University, College of Physician and Surgeons
2009-present
Associate Director, Gunnar Esiason Adult Cystic Fibrosis and Lung Center
Columbia University Medical Center
2009-present
Committees and Collaboratives:
Cystic Fibrosis Foundation Therapeutics, Inc.
Data Safety and Monitoring Board Member
2012-present
Cystic Fibrosis Foundation Therapeutic Drug Network
Publications and Presentations Committee Member
2012-present
NYC-Clinical Data Research Network
Stakeholder Advisory Board Member
2014-present
Hospital Appointments:
Assistant Professor of Clinical Medicine
New York Presbyterian Hospital-Columbia Medical Center
2006-present
Past Awards:
Honors in Biological Sciences Major, Cornell University
Golden Key National Honor Society, Cornell University
Presidential Award for Citizenship and Public Service, Tufts University
Daniel M. Libby Program Director’s Award for Clinical Excellence;
Cornell Medical Center
Adult Quality Improvement 3 Learning and Leadership Collaborative Award;
Cystic Fibrosis Foundation, Team Champion
OneCF Learning and Leadership Collaborative 2 Award
Cystic Fibrosis Foundation, Team Leader
1997
1997
2001
2006
2013
2015
Lectures, teaching and responsibilities:
Cystic Fibrosis and the Adult Patient
Medicine Grand Rounds
Methodist Hospital, Brooklyn, NY
March 2012
Bronchiectasis diagnosis and management:
Annual pulmonary fellowship didactic seminar
Columbia University Medical Center
2010-present
Cystic Fibrosis diagnosis and management:
Annual allergy fellowship didactic seminar
Columbia University Medical Center
2012-present
Pulmonary Consultation Attending Physician
Columbia University Medical Center
2009-present
Pulmonary Function Test interpretation preceptor
Columbia University Medical Center
2009-present
Research Activity:
A Phase 3, Randomized, Double Blind, Placebo Controlled Parallel-Group
7/2015
Study to Evaluate the Efficacy and Safety of VX661 in Combination with
Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Heterozygous
for F508del-CFTR Mutation and With a Second CFTR Mutation that is
Not Likely to Respond to VX-661 and/or Ivacaftor Therapy
Vertex Pharmaceuticals Inc.
Role: Principal Investigator
A Multicenter, Randomized Double Blind, Placebo Controlled
04/2015-present
Study to Evaluate the Efficacy and Safety of Pulmaquin in the Management
Chronic Lung Infections with Pseudomonas in Subjects with Non-Cystic Fibrosis
Bronchiectasis
Aradigm Corporation
Role: Co-Investigator
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with
Nonsense Mutation Cystic Fibrosis
PTC Therapeutics
Role: Co-Investigator
03/2015-present
A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled
Study to Evaluate Safety, Efficacy, Pharmacokinetics, and
Pharmacodynamics of VX 661 in Combination with Ivacaftor for
12 Weeks in Subjects with Cystic Fibrosis, Homozygous for the F508del
CFTR Mutation
Vertex Pharmaceuticals Inc.
Role: Principal Investigator
04/2014-present
A Phase 2, Multicenter, Double Blind, Placebo Controlled, Multiple Dose
Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and
Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and
Ivacaftor Combination Therapy in Subjects with Cystic Fibrosis,
Homozygous or Heterozygous for the F508del-CFTR Mutation—Cohort 4
Vertex Pharmaceuticals Inc.
Role: Principal Investigator
06/2013-present
Cystic Fibrosis Foundation
C079-TDC09Y
Columbia University Therapeutics Development Network
Role: Co-PI
01/01/10-present
Publications:
Wiedmann M, Bruce JL, Keating C, Johnson AE, McDonough PL, Batt CA.
Ribotypes and virulence gene polymorphisms suggest three distinct Listeria
monocytogenes lineages with differences in pathogenic potential. Infection & Immunity
1997 Jul;65(7):2707-16.
Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK,
Sprague KA, Miller KB, Schenkein DP. Randomized trial of filgrastim versus chemotherapy and filgrastim
mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001 Oct
1;98(7):2059-64.
Keating C, Wang S, Brenner K, Wang T, Powell C. Circulating Progenitor Cells in Non-Small Cell Lung
Cancer Patients. Poster presentation, American Thoracic Society Annual Meetings, Toronto, Canada
2008. Am. J. Respir. Critical Care Med, 2008.
Keating C, Liu X, DiMango E. Characteristics of Adult Diagnosis of CF from the CF Foundation Registry.
Poster Presentation, North American Cystic Fibrosis Conference, Orlando, FL 2008. Pediatric
Pulmonology, 2008.
Keating C, Liu X, DiMango E. Predictors of Lung Function in Cystic Fibrosis at Diagnosis. Poster Discussion
Session, American Thoracic Society Annual Meetings, San Diego 2009. Am. J. Respir. Critical Care Med,
2009.
Keating, C. L., D'Souza, B. M., Mason, D. M., Shu, C. A.; DiMango, E. A., Austin, J. H.M. Adult-Diagnosis of
CF – Does it Differ at CT Scan from the Pediatric Population? North American Cystic Fibrosis Conference,
Minneapolis, MN 2009. Pediatric Pulmonology, 2009.
Keating CL, Liu X, Dimango EA,; Classic respiratory disease but atypical diagnostic testing distinguishes
adult presentation of cystic fibrosis. Chest. 2010 May;137(5):1157-63.
Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, et al. Effect of
esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med. 2014 Feb
15;14:21.
Keating C, Poor A, Liu X, Dimango E. Delayed diagnosis of cystic fibrosis have slower FEV1 decline but
higher risk of death or transplant over time. Workshop Presentation, North American Cystic Fibrosis
Conference, Atlanta, GA 2014. Pediatric Pulmonology, 2014.
Fly UP